Vaccines and Thiomersal
Introduction to Thiomersal in Vaccines
- Since mid-2001, vaccines recommended for children have been manufactured without thiomersal as a preservative, containing either no thiomersal or only trace amounts (<1 mcg mercury/dose), as recommended by health organizations such as the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) 1, 2
- The CDC and AAP recommend the use of reduced thimerosal-content versions of influenza vaccine when available 3, 2
Thiomersal Content in Vaccines
- Multi-dose vials of certain vaccines, including Td (Tetanus and diphtheria toxoids) and DT (Diphtheria and tetanus toxoids) vaccines, still contain thiomersal as a preservative (approximately 25 mcg mercury/0.5 mL dose) 4, 1, 2
- Live attenuated vaccines, such as MMR (measles, mumps, rubella), varicella, and live attenuated influenza vaccine, have never contained thiomersal 2
- Single-dose presentations are mostly thiomersal-free or contain only trace amounts, less than 1 mcg mercury/dose 5, 6
- The following table summarizes thiomersal content in vaccines:
| Vaccine Type | Thiomersal Content |
|---|---|
| Multi-dose vials (e.g. Td, DT) | 25 mcg mercury/0.5 mL dose |
| Single-dose presentations | <1 mcg mercury/dose |
| Live attenuated vaccines | None |
Safety and Efficacy of Thiomersal
- The elimination of mercury from vaccines has been primarily a precautionary measure, with no scientific evidence indicating that thiomersal in vaccines leads to serious adverse events 1, 3, 5
- Hypersensitivity to thiomersal usually consists of local delayed-type hypersensitivity reactions, but is not a contraindication to receipt of a vaccine that contains thiomersal 1, 2
- The benefits of vaccination are considered to outweigh theoretical risks from thiomersal exposure, especially in settings where multi-dose vials are the only option 5, 6
Recommendations for Vaccine Administration
- Package inserts should be consulted for information about specific vaccine formulations 4
- The benefit of influenza vaccine with reduced or standard thiomersal content outweighs the theoretical risk from thiomersal, and delaying vaccination to wait for thiomersal-free formulations could leave patients vulnerable to preventable diseases 3, 2, 6
- When available and permitted by state law, single-dose, thiomersal-free formulations are generally preferred for infants and pregnant women, though in settings where multi-dose vials are the only option, the benefits of vaccination outweigh theoretical risks from thiomersal exposure 5, 6
- The American Academy of Pediatrics (AAP) and the World Health Organization support the continued use of thiomersal as a preservative in multi-dose vials in the global vaccine supply, considering the benefits of timely vaccination to outweigh theoretical risks from thiomersal exposure 6